Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap26.09B
Market cap26.09B
Price-Earnings ratio16.22
Price-Earnings ratio16.22
Dividend yield—
Dividend yield—
Average volume2.56M
Average volume2.56M
High today$178.24
High today$178.24
Low today$174.28
Low today$174.28
Open price$175.37
Open price$175.37
Volume1.07M
Volume1.07M
52 Week high$185.17
52 Week high$185.17
52 Week low$110.04
52 Week low$110.04
Stock Snapshot
With a market cap of 26.09B, Biogen(BIIB) trades at $177.82. The stock has a price-to-earnings ratio of 16.22.
As of 2026-01-04, Biogen(BIIB) stock has fluctuated between $174.28 and $178.24. The current price stands at $177.82, placing the stock +2.0% above today's low and -0.2% off the high.
The Biogen(BIIB)'s current trading volume is 1.07M, compared to an average daily volume of 2.56M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $185.17 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $185.17 at its peak.
Analyst ratings
49%
of 35 ratingsBuy
45.7%
Hold
48.6%
Sell
5.7%
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.